Endometrial Cancer

Faeth Therapeutics Highlights PIKTOR Strategy Ahead of Phase 2 Data

AUSTIN, Texas — September 8, 2026 Faeth Therapeutics announced plans to host a virtual key opinion leader (KOL) event...

By cGxPwire Editor
September 9, 2026

Bio-Pharma

Faeth Therapeutics Gains FDA Fast Track for PIKTOR

Austin, Texas — August 17, 2026 Faeth Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted...

By cGxPwire Editor
August 18, 2026

Bio-Pharma

Faeth Therapeutics to Present PIKTOR PK/PD Data

AUSTIN, Texas, August 7, 2026 Faeth Therapeutics announced that it will present new pharmacokinetic/pharmacodynamic (PK/PD) modeling and translational research...

By cGxPwire Editor
August 8, 2026

Bio-Pharma

MacroGenics Reports Positive Phase 1 MGC026 Cancer Study Update

ROCKVILLE, MD, July 23, 2026 MacroGenics, Inc. announced a significant clinical update from its ongoing Phase 1 study of...

By cGxPwire Editor
July 24, 2026

M&A

Merck Animal Health Acquires TARGAN to Advance Poultry Technology

RAHWAY, N.J., June 11, 2026 Merck Animal Health, a division of Merck & Co., Inc., has signed a definitive...

By cGxPwire Editor
June 13, 2026

Find Jobs Across Pharma, Biotech & Life Sciences

Discover verified job opportunities from top companies worldwide. Apply easily and grow your career in the life sciences industry.

MedTech

Roche Expands VENTANA MMR Companion Diagnostic Across Multiple Cancer Types

TUCSON, Arizona, USA, June 11, 2026 Roche Diagnostics has announced a significant expansion of its precision oncology diagnostics portfolio...

By cGxPwire Editor
June 12, 2026

.Clinical

Merck Sac-TMT Trial Shows Survival Benefit in Cancer

Rahway, N.J., USA – May 18, 2026 Merck announced that its pivotal Phase 3 TroFuse-005 clinical trial evaluating sacituzumab...

By cGxPwire Editor
May 23, 2026

Bio-Pharma

GSK Reports Strong ADC Data in Ovarian Cancer Study

London, United Kingdom | April 13, 2026 GSK plc has announced positive clinical data from its Phase 1 BEHOLD-1...

By cGxPwire Editor
April 14, 2026

Bio-Pharma

Whitehawk Therapeutics Identifies PTK7 as a Broadly Expressed ADC Target Across Solid Tumors

MORRISTOWN, N.J. | October 24, 2025 — Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology-focused biopharmaceutical company pioneering next-generation antibody-drug...